Skip to content

Study on the relationship between oral volatile sulfur compounds and lactic acid bacteria.

SP1665 - SP1665

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000042297
Enrollment
40
Registered
2020-10-30
Start date
2020-11-05
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adults

Interventions

Beverage containing an ingredient. Beverage without any ingredients.

Sponsors

Otsuka Pharmaceutical,Co.,Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Subjects who gave written informed consent to participate in the study. 2) Individuals who are diagnosed as having no health problems based on a physician's interview. 3) Men and women aged 20-65 years at the time of informed consent. 4) Non-smokers for at least 1 year. 5) Persons who have not undergone dental treatment or cleaning by a dentist within 6 months retrospectively from the date of the screening examination. 6) Those who have 24 or more teeth left behind.

Exclusion criteria

Exclusion criteria: 1) Pregnant women or women of childbearing potential, and women who wish to become pregnant during the study period. 2) Lactating women. 3) Persons with a history of serious disease (including Sjoegren's syndrome). 4) Persons who may require dental treatment (including orthodontic treatment) during the study participation period. 5) Persons who has undergone extraction procedures other than tooth extraction for convenience in wisdom tooth extraction or orthodontic treatment. 6) Patients who have taken antibiotics within 3 months. 7) Persons who may use antihistamines (due to hay fever, allergies, etc.) during the study period (use of antihistamines and cold medications will be investigated in a pre-questionnaire or diary). 8) Persons who do not show an increase in oral gas concentration after wearing a mask in the measurement of oral gas concentration during screening. 9) Other persons who the investigator or the investigator judges to be inappropriate as subjects of the study.

Design outcomes

Primary

MeasureTime frame
Amount of change in oral gas concentration.

Secondary

MeasureTime frame
Analysis of oral flora (e.g. correlation with volatile sulfide compounds).

Countries

Japan

Contacts

Public ContactHiroshi Saito

Otsuka Pharmaceutical,Co.,Ltd. Otsu Nutraceuticals Research Institute

Saito.Hiroshi@otsuka.jp077-521-8835

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026